Diabetes & Metabolism Journal

Brief Reports

Genetics
Clinical Characteristics of Diabetes in People with Mitochondrial DNA 3243A>G Mutation in Korea: Eun Hoo Rho, Sang Ik Baek, Heerah Lee, Moon-Woo Seong, Jong-Hee Chae, Kyong Soo Park, Soo Heon Kwak; Received March 10, 2023 Accepted July 20, 2023 Published online February 1, 2024; DOI: https://doi.org/10.4093/dmj.2023.0078 [Epub ahead of print]

524 View
32 Download

Abstract PDF Supplementary Material PubReader ePub: Maternally inherited diabetes and deafness (MIDD) is a rare mitochondrial disorder primarily resulting from m.3243A>G mutation. The clinical characteristics of MIDD exhibit significant heterogeneity. Our study aims to delineate these characteristics and determine the potential correlation with m.3243A>G heteroplasmy levels. This retrospective, descriptive study encompassed patients with confirmed m.3243A>G mutation and diabetes mellitus at Seoul National University Hospital. Our cohort comprises 40 patients with MIDD, with a mean age at study enrollment of 33.3±12.9 years and an average % of heteroplasmy of 30.0%± 14.6% in the peripheral blood. The most prevalent comorbidity was hearing loss (90%), followed by albuminuria (61%), seizure (38%), and stroke (33%). We observed a significant negative correlation between % of heteroplasmy and age at diabetes diagnosis. These clinical features can aid in the suspicion of MIDD and further consideration of genetic testing for m.3243A>G mutation.

Metabolic Risk/Epidemiology
Trends in the Prevalence of Obesity and Its Phenotypes Based on the Korea National Health and Nutrition Examination Survey from 2007 to 2017 in Korea: Sang Ouk Chin, You-Cheol Hwang, Hong-Yup Ahn, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung; Diabetes Metab J. 2022;46(5):808-812. Published online March 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0226

3,934 View
216 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

This study used data from the Korea National Health and Nutrition Examination Survey IV–VII from 2007 to identify the prevalence of obesity and its phenotypes (metabolically unhealthy obesity [MUO] and metabolically healthy obesity [MHO]) and their secular changes. The prevalence of obesity in Korea increased with significant secular changes observed (β=0.326, P trend <0.01) between 2007 and 2017, and especially in men (β=0.682, P trend <0.001) but not in women. The changes in the prevalence of obesity during the study period were different between men and women (P=0.001). The prevalence of MUO significantly increased only in men (β=0.565, P trend <0.01), while that of MHO increased only in women (β=0.179, P<0.05), especially in the younger age group (β=0.308, P<0.01).

Citations

Citations to this article as recorded by

Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh, Kyung Mook Choi
International Journal of Molecular Sciences.2023; 24(4): 3384. CrossRef
Differences of Regional Fat Distribution Measured by Magnetic Resonance Imaging According to Obese Phenotype in Koreans
Ha-Neul Choi, Hyunjung Lim, Young-Seol Kim, Sang-Youl Rhee, Jung-Eun Yim
Metabolic Syndrome and Related Disorders.2022; 20(10): 551. CrossRef

Metabolic Risk/Epidemiology
Rising Incidence of Diabetes in Young Adults in South Korea: A National Cohort Study: Hyun Ho Choi, Giwoong Choi, Hojun Yoon, Kyoung Hwa Ha, Dae Jung Kim; Diabetes Metab J. 2022;46(5):803-807. Published online January 11, 2022; DOI: https://doi.org/10.4093/dmj.2021.0236

65,535 View
390 Download
5 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

We investigated the incidence of diagnosed diabetes in South Korean adults (aged ≥20 years) by analyzing data for the National Health Insurance Service–National Sample Cohort. From 2006 to 2015, the overall incidence rate of diagnosed diabetes decreased by approximately 0.1% per year until 2015. Although, this trend was observed in individuals aged 40 years or over, the rate increased slightly in the 20–29 and 30–39 years age groups, from 0.5 to 0.7 and 2.0 to 2.6 per 1,000 individuals, respectively. The proportion of obese young adults with diabetes increased remarkably, from 51.4% in 2006 to 72.4% in 2015. Thus, young adults need early identification and weight-control strategies to prevent diabetes.

Citations

Citations to this article as recorded by

Cumulative exposure to hypertriglyceridemia and risk of type 2 diabetes in young adults
Min-Kyung Lee, Kyungdo Han, Bongsung Kim, Jong-Dai Kim, Moon Jung Kim, Byungpyo Kim, Jung Heo, Jiyeon Ahn, Seo-Young Sohn, Jae-Hyuk Lee
Diabetes Research and Clinical Practice.2024; 208: 111109. CrossRef
Young-Onset Diabetes in East Asians: From Epidemiology to Precision Medicine
Juliana C.N. Chan, Chun-Kwan O, Andrea O.Y. Luk
Endocrinology and Metabolism.2024; 39(2): 239. CrossRef
Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes
Kyoung Hwa Ha, Kyung Ae Lee, Kyung-Do Han, Min Kyong Moon, Dae Jung Kim
The Korean Journal of Internal Medicine.2023; 38(1): 93. CrossRef
Revisiting the Diabetes Crisis in Korea: Call for Urgent Action
Jun Sung Moon
The Journal of Korean Diabetes.2023; 24(1): 1. CrossRef
Position Statement on the Appropriateness and Significance of Adding the Glycated Hemoglobin Test to the National Health Examination
Ji Hye Kim, Dae Jung Kim, Jaehyun Kim, Sangjoon Park, Kyunghoon Lee, Jun Goo Kang, Eu Jeong Ku, Su Kyoung Kwon, Won Jun Kim, Young Sang Lyu, Jang Won Son, Young Sil Eom, Kyung Ae Lee, Jeongrim Lee, Jung Min Lee, Jung Hwa Lee, Jung Hwa Jung, Hochan Cho, Da
The Journal of Korean Diabetes.2023; 24(4): 178. CrossRef
Diabetes Fact Sheet in Korea 2021
Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
Diabetes & Metabolism Journal.2022; 46(3): 417. CrossRef
젊은 2형 당뇨병 환자의 관리
재현 배
Public Health Weekly Report.2022; 15(35): 2474. CrossRef
Screening for Prediabetes and Diabetes in Korean Nonpregnant Adults: A Position Statement of the Korean Diabetes Association, 2022
Kyung Ae Lee, Dae Jung Kim, Kyungdo Han, Suk Chon, Min Kyong Moon
Diabetes & Metabolism Journal.2022; 46(6): 819. CrossRef

Technology/Device
Do-It-Yourself Open Artificial Pancreas System in Children and Adolescents with Type 1 Diabetes Mellitus: Real-World Data: Min Sun Choi, Seunghyun Lee, Jiwon Kim, Gyuri Kim, Sung Min Park, Jae Hyeon Kim; Diabetes Metab J. 2022;46(1):154-159. Published online November 23, 2021; DOI: https://doi.org/10.4093/dmj.2021.0011

5,324 View
193 Download
5 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Few studies have been conducted among Asian children and adolescents with type 1 diabetes mellitus (T1DM) using do-it-yourself artificial pancreas system (DIY-APS). We evaluated real-world data of pediatric T1DM patients using DIY-APS. Data were obtained for 10 patients using a DIY-APS with algorithms. We collected sensor glucose and insulin delivery data from each participant for a period of 4 weeks. Average glycosylated hemoglobin was 6.2%±0.3%. The mean percentage of time that glucose level remained in the target range of 70 to 180 mg/dL was 82.4%±7.8%. Other parameters including time above range, time below range and mean glucose were also within the recommended level, similar to previous commercial and DIY-APS studies. However, despite meeting the target range, unadjusted gaps were still observed between the median basal setting and temporary basal insulin, which should be handled by healthcare providers.

Citations

Citations to this article as recorded by

Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2023; 47(1): 27. CrossRef
Open-source automated insulin delivery systems (OS-AIDs) in a pediatric population with type 1 diabetes in a real-life setting: the AWeSoMe study group experience
Judith Nir, Marianna Rachmiel, Abigail Fraser, Yael Lebenthal, Avivit Brener, Orit Pinhas-Hamiel, Alon Haim, Eve Stern, Noa Levek, Tal Ben-Ari, Zohar Landau
Endocrine.2023; 81(2): 262. CrossRef
Efficacy and safety of Android artificial pancreas system use at home among adults with type 1 diabetes mellitus in China: protocol of a 26-week, free-living, randomised, open-label, two-arm, two-phase, crossover trial
Mengyun Lei, Beisi Lin, Ping Ling, Zhigu Liu, Daizhi Yang, Hongrong Deng, Xubin Yang, Jing Lv, Wen Xu, Jinhua Yan
BMJ Open.2023; 13(8): e073263. CrossRef
Barriers to Uptake of Open-Source Automated Insulin Delivery Systems: Analysis of Socioeconomic Factors and Perceived Challenges of Caregivers of Children and Adolescents With Type 1 Diabetes From the OPEN Survey
Antonia Huhndt, Yanbing Chen, Shane O’Donnell, Drew Cooper, Hanne Ballhausen, Katarzyna A. Gajewska, Timothée Froment, Mandy Wäldchen, Dana M. Lewis, Klemens Raile, Timothy C. Skinner, Katarina Braune
Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Toward Personalized Hemoglobin A1c Estimation for Type 2 Diabetes
Namho Kim, Da Young Lee, Wonju Seo, Nan Hee Kim, Sung-Min Park
IEEE Sensors Journal.2022; 22(23): 23023. CrossRef

Metabolic Risk/Epidemiology
Short-Term Effects of the Internet-Based Korea Diabetes Prevention Study: 6-Month Results of a Community-Based Randomized Controlled Trial: Jin-Hee Lee, Sun-Young Lim, Seon-Ah Cha, Chan-Jung Han, Ah Reum Jung, Kook-Rye Kim, Kun-Ho Yoon, Seung-Hyun Ko; Diabetes Metab J. 2021;45(6):960-965. Published online March 17, 2021; DOI: https://doi.org/10.4093/dmj.2020.0225

5,450 View
151 Download
5 Web of Science
6 Crossref

Graphical Abstract Abstract PDF PubReader ePub

The aims of this study were to determine the short-term effectiveness of an internet-based lifestyle modification (LSM) program in preventing the onset of type 2 diabetes mellitus (T2DM) in prediabetes patients in community settings. A total of 415 subjects who were diagnosed with prediabetes were randomly assigned to the LSM and standard management (SM) groups. After the 6-month intervention, the LSM group had a statistically significant reduction in body weight, body mass index compared to the SM group participants. In the LSM group, blood glucose levels were significantly decreased after intervention and the clinical improvement effect was evident in the group that achieved the target weight loss of 5% or more of the initial weight for 6 months. Internet-based 6-month-intensive LSM programs conducted by public health center personnel are an effective way to provide lifestyle intervention programs and encourage maintenance of healthy behaviors in subjects with a high risk of T2DM in community settings.

Citations

Citations to this article as recorded by

U-shaped association between online information exchange and app usage frequency: a large-scale survey of China ‘s online young and middle-aged people with pre diabetes and diabetes
Hanbin Guo, Yibiao Xiao, Canlin Liao, Jiating Sun, Yanchun Xie, Yitong Zheng, Guanhua Fan
Frontiers in Endocrinology.2023;[Epub] CrossRef
Innovation in diabetes prevention research: The 36-year legacy of China Da Qing diabetes prevention study
Xin Chai, Yachen Wang, Jinping Wang, Qiuhong Gong, Juan Zhang, Ruitai Shao
Chinese Science Bulletin.2023; 68(28-29): 3834. CrossRef
Efficacy of Personalized Diabetes Self-care Using an Electronic Medical Record–Integrated Mobile App in Patients With Type 2 Diabetes: 6-Month Randomized Controlled Trial
Eun Young Lee, Seon-Ah Cha, Jae-Seung Yun, Sun-Young Lim, Jin-Hee Lee, Yu-Bae Ahn, Kun-Ho Yoon, Min Kyung Hyun, Seung-Hyun Ko
Journal of Medical Internet Research.2022; 24(7): e37430. CrossRef
Prevention of type 2 diabetes through remotely administered lifestyle programs: A systematic review
Valaree Villegas, Alisha Shah, JoAnn E. Manson, Deirdre K. Tobias
Contemporary Clinical Trials.2022; 119: 106817. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
Diabetes & Metabolism Journal.2021; 45(4): 461. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Seung-Hyun Ko
The Journal of Korean Diabetes.2021; 22(4): 244. CrossRef

Complications
Trends in the Incidence, Prevalence, and Mortality of End-Stage Kidney Disease in South Korea: Min-Jeong Lee, Kyoung Hwa Ha, Dae Jung Kim, Inwhee Park; Diabetes Metab J. 2020;44(6):933-937. Published online December 23, 2020; DOI: https://doi.org/10.4093/dmj.2020.0156

5,849 View
239 Download
12 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Knowledge of the epidemiologic characteristics of end-stage kidney disease (ESKD) patients is essential. The trends in the prevalence, incidence, and mortality rates of ESKD were analyzed retrospectively using the Korean National Health Insurance ServiceNational Sample Cohort database between 2006 and 2015. From 2006 to 2015, the incidence of ESKD decreased from 28.6 to 24.0 per 100,000 people and showed a decreasing pattern with or without diabetes mellitus. However, the incidence of those aged ≥75 years increased, as did the mean age at the onset of ESKD. From 2007 to 2015, the prevalence of ESKD increased in all age groups, but particularly in those aged ≥75 years. The prevalence of ESKD differed by sex and diabetes mellitus status and this gap widened over time. Mortality rates in ESKD patients remained relatively constant throughout the study period. However, mortality rates in ESKD without diabetes decreased over the same period.

Citations

Citations to this article as recorded by

Kidney Health Plan 2033 in Korea: bridging the gap between the present and the future
Do Hyoung Kim, Young Youl Hyun, Jin Joo Cha, Sua Lee, Hyun Kyung Lee, Jong Wook Choi, Su-Hyun Kim, Sang Youb Han, Cheol Whee Park, Eun Young Lee, Dae Ryong Cha, Sung Gyun Kim, Chun Soo Lim, Sun-Hee Park
Kidney Research and Clinical Practice.2024; 43(1): 8. CrossRef
Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Research and Clinical Practice.2024; 210: 111639. CrossRef
Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585. CrossRef
Usefulness of continuous glucose monitoring of blood glucose control in patients with diabetes undergoing hemodialysis: A pilot study
Sua Lee, Soyoung Lee, Kyeong Min Kim, Jong Ho Shin
Frontiers in Medicine.2023;[Epub] CrossRef
Association between N-Terminal Prohormone Brain Natriuretic Peptide and Decreased Skeletal Muscle Mass in a Healthy Adult Population: A Cross-Sectional Study
Tae Kyung Yoo, Marie Yung-Chen Wu, Moon Soo Kim, Mi-Yeon Lee, Yong-Taek Lee, Kyung Jae Yoon, Chul-Hyun Park
Endocrinology and Metabolism.2023; 38(2): 269. CrossRef
Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018
Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee
Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef
Epigenome-wide association study of diabetic chronic kidney disease progression in the Korean population: the KNOW-CKD study
Hye Youn Sung, Sangjun Lee, Miyeun Han, Woo Ju An, Hyunjin Ryu, Eunjeong Kang, Yong Seek Park, Seung Eun Lee, Curie Ahn, Kook-Hwan Oh, Sue K. Park, Jung-Hyuck Ahn
Scientific Reports.2023;[Epub] CrossRef
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Kieran F. Docherty, Inder S. Anand, Chern-En Chiang, Vijay K. Chopra, Akshay S. Desai, Masafumi Kitakaze, Subodh Verma, Pham N. Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabat
JACC: Asia.2022; 2(2): 139. CrossRef
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef
The risk of Parkinson's disease according to diabetic kidney disease status in a Korean population
Seung Eun Lee, Juhwan Yoo, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Parkinsonism & Related Disorders.2022; 100: 13. CrossRef
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
Nam Hoon Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(4): 543. CrossRef
The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study
Jun Hyoung Kim, Heeseon Jang, Jung Ho Kim, Joon Young Song, Shin-Woo Kim, Sang Il Kim, Bo Youl Choi, Jun Yong Choi
Infection & Chemotherapy.2022; 54(3): 534. CrossRef
Sex difference in the association among nutrition, muscle mass, and strength in peritoneal dialysis patients
Jun Young Do, Seok Hui Kang
Scientific Reports.2022;[Epub] CrossRef
Additive interaction of diabetes mellitus and chronic kidney disease in cancer patient mortality risk
Seohyun Kim, Gyuri Kim, Jae Hyeon Kim
Scientific Reports.2022;[Epub] CrossRef

Complications
Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015): Seong-Su Moon, Chong Hwa Kim, Seon Mee Kang, Eun Sook Kim, Tae Jung Oh, Jae-Seung Yun, Ho Chan Cho, Dae Jung Kim, Tae Sun Park; Diabetes Metab J. 2021;45(1):115-119. Published online December 18, 2020; DOI: https://doi.org/10.4093/dmj.2020.0120

7,069 View
275 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

This report presents the status of diabetic neuropathy (DN) in Korea as determined using a National Health Insurance ServiceNational Sample Cohort (NHIS-NSC). Annual prevalences of DN were estimated by age and gender using descriptive statistics. Pharmacological treatments for DN were also analyzed. The annual prevalence of DN increased from 24.9% in 2006 to 26.6% in 2007, and thereafter, gradually subsided to 20.8% in 2015. In most cases, pharmacological treatments involved a single drug, which accounted for 91.6% of total prescriptions in 2015. The most commonly used drugs (in decreasing order) were thioctic acid, an anti-convulsive agent, or a tricyclic antidepressant. In conclusion, the prevalence of DN decreased over the 10-year study period. Thioctic acid monotherapy was usually prescribed for DN. To reduce the socio-economic burden of DN, more attention should be paid to the diagnosis of this condition and to the appropriate management of patients.

Citations

Citations to this article as recorded by

Risk of cardiovascular events according to the tricyclic antidepressant dosage in patients with chronic pain: a retrospective cohort study
Hyunji Koo, Seung Hun You, Sewon Park, Kyeong Hye Jeong, Nakyung Jeon, Sun-Young Jung
European Journal of Clinical Pharmacology.2023; 79(1): 159. CrossRef
How does diabetic peripheral neuropathy impact patients' burden of illness and the economy? A retrospective study in Beijing, China
Qi Pan, Sijia Fei, Lina Zhang, Huan Chen, Jingyi Luo, Weihao Wang, Fei Xiao, Lixin Guo
Frontiers in Public Health.2023;[Epub] CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
BMC Public Health.2023;[Epub] CrossRef
Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy
Han Na Jang, Tae Jung Oh
Diabetes & Metabolism Journal.2023; 47(6): 743. CrossRef
Are herbal medicines alone or in combination for diabetic peripheral neuropathy more effective than methylcobalamin alone? A systematic review and meta-analysis
Chang-Woo Lee, Joon-Soo Jin, Seungwon Kwon, Chul Jin, Seung-Yeon Cho, Seong-Uk Park, Woo-Sang Jung, Sang-Kwan Moon, Jung-Mi Park, Chang-Nam Ko, Ki-Ho Cho
Complementary Therapies in Clinical Practice.2022; 49: 101657. CrossRef
Pathogenesis and Treatment of Diabetic Peripheral Neuropathy
Seon Mee Kang
The Journal of Korean Diabetes.2022; 23(4): 222. CrossRef
Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015) (Diabetes Metab J 2021;45:115-9)
Seong-Su Moon, Chong Hwa Kim, Seon Mee Kang, Eun Sook Kim, Tae Jung Oh, Jae-Seung Yun, Ho Chan Cho, Dae Jung Kim, Tae Sun Park
Diabetes & Metabolism Journal.2021; 45(3): 459. CrossRef
Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015) (Diabetes Metab J 2021;45:115-9)
Tímea Csákvári, Diána Elmer, Lilla Horváth, Imre Boncz
Diabetes & Metabolism Journal.2021; 45(3): 454. CrossRef
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78)
Ja Young Jeon
Diabetes & Metabolism Journal.2021; 45(4): 613. CrossRef
Diffculties and ways to overcome them in selection of therapy for pain syndromes in patients with diabetes mellitus
K. A. Makhinov, P. R. Kamchatnov
Medical alphabet.2021; (22): 25. CrossRef

Complications
Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea: Jung Hwan Park, Kyoung Hwa Ha, Bo Yeon Kim, Jae Hyuk Lee, Dae Jung Kim; Diabetes Metab J. 2021;45(1):120-124. Published online December 9, 2020; DOI: https://doi.org/10.4093/dmj.2020.0175; Correction in: Diabetes Metab J 2021;45(2):283

11,832 View
352 Download
32 Web of Science
37 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

We investigated the cardiovascular complications and mortality rates of patients with diabetes in South Korea. The rates of hospitalization due to cardiovascular complications and mortality were analyzed using the Korean National Health Insurance Service-National Sample Cohort. From 2006 to 2015, the rates of hospitalization due to major cardiovascular complications decreased, while those due to heart failure (from 72 to 146 and 124 to 161 per 10,000 men and women, respectively) and peripheral artery disease (from 39 to 55 and 19 to 35 per 10,000 men and women, respectively) increased. In the period 2007 to 2015, the mortality rates for cancer, cerebrovascular disease, diabetes, heart disease, and hypertensive disease all decreased. However, the mortality rate for pneumonia increased. We observed a continuous reduction in cardiovascular complications and mortality in adults with diabetes. However, with the increase in some diabetes complications, more efforts are needed to prevent diabetes complications.

Citations

Citations to this article as recorded by

Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
PLOS ONE.2024; 19(2): e0299035. CrossRef
Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study
Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Research and Clinical Practice.2024; 210: 111639. CrossRef
Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century
Peter A. Lazzarini, Susanna M. Cramb, Jonathan Golledge, Jedidiah I. Morton, Dianna J. Magliano, Jaap J. Van Netten
Diabetologia.2023; 66(2): 267. CrossRef
Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England
Suping Ling, Francesco Zaccardi, Eyad Issa, Melanie J. Davies, Kamlesh Khunti, Karen Brown
Diabetologia.2023; 66(4): 657. CrossRef
Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Journal of Lipid and Atherosclerosis.2023; 12(1): 12. CrossRef
Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
International Journal of Heart Failure.2023; 5(1): 1. CrossRef
Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino
Journal of Diabetes Investigation.2023; 14(3): 417. CrossRef
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 1. CrossRef
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef
The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study
Seung Eun Lee, Juhwan Yoo, Bong-Seong Kim, Han Seok Choi, Kyungdo Han, Kyoung-Ah Kim
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
Diabetes & Metabolism Journal.2023; 47(2): 201. CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
BMC Public Health.2023;[Epub] CrossRef
The Present and Future of Artificial Intelligence-Based Medical Image in Diabetes Mellitus: Focus on Analytical Methods and Limitations of Clinical Use
Ji-Won Chun, Hun-Sung Kim
Journal of Korean Medical Science.2023;[Epub] CrossRef
The Role of Echocardiography in Evaluating Cardiovascular Diseases in Patients with Diabetes Mellitus
Sun Hwa Lee, Jae-Hyeong Park
Diabetes & Metabolism Journal.2023; 47(4): 470. CrossRef
Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea
Ji Hye Huh, Serim Kwon, Gui Ok Kim, Bo Yeon Kim, Kyoung Hwa Ha, Dae Jung Kim
Diabetes Care.2023; 46(9): 1700. CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus
Kyung Ae Lee
The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
Ye Seul Yang
The Journal of Korean Diabetes.2023; 24(3): 135. CrossRef
Interpreting global trends in type 2 diabetes complications and mortality
Mohammed K. Ali, Jonathan Pearson-Stuttard, Elizabeth Selvin, Edward W. Gregg
Diabetologia.2022; 65(1): 3. CrossRef
Cardiovascular disease in patients with type 2 diabetes
Ja Young Jeon, Dae Jung Kim
Journal of Diabetes Investigation.2022; 13(4): 614. CrossRef
Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2022; 4(1): 42. CrossRef
Editorial: Management of Diabetes and its Complications: A Focus on Endothelial Dysfunction
Shanhu Qiu, Jianhua Ma, Tongzhi Wu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Smoking, Metabolic Syndrome, and Cardiovascular Disease
Seo Young Kang
Korean Journal of Family Practice.2022; 12(2): 59. CrossRef
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Cheng-Xu Ma, Xiao-Ni Ma, Cong-Hui Guan, Ying-Dong Li, Dídac Mauricio, Song-Bo Fu
Cardiovascular Diabetology.2022;[Epub] CrossRef
Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
Journal of Diabetes Investigation.2022; 13(9): 1533. CrossRef
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sung
Diabetes & Metabolism Journal.2022; 46(3): 464. CrossRef
Diabetes Fact Sheet in Korea 2021
Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won
Diabetes & Metabolism Journal.2022; 46(3): 417. CrossRef
Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus
Jeongmin Lee, Jae-Seung Yun, Seung-Hyun Ko
Nutrients.2022; 14(15): 3086. CrossRef
Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
Nam Hoon Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(4): 543. CrossRef
Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
Diabetes Research and Clinical Practice.2022; 191: 110067. CrossRef
Blood Pressure Target in Type 2 Diabetes Mellitus
Hyun-Jin Kim, Kwang-il Kim
Diabetes & Metabolism Journal.2022; 46(5): 667. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Trends in diabetes-related complications in Singapore, 2013–2020: A registry-based study
Joshua Kuan Tan, Nur Nasyitah Mohamed Salim, Gek Hsiang Lim, Sing Yi Chia, Julian Thumboo, Yong Mong Bee, Ferdinando Carlo Sasso
PLOS ONE.2022; 17(10): e0275920. CrossRef
Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
Endocrinology and Metabolism.2022; 37(5): 759. CrossRef
Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes
Seon-Ah Cha, Jae-Seung Yun, Gee-Hee Kim, Yu-Bae Ahn
Cardiovascular Diabetology.2022;[Epub] CrossRef
Heart Failure and Diabetes Mellitus: Dangerous Liaisons
Hae-Young Lee
International Journal of Heart Failure.2022; 4(4): 163. CrossRef
Diabetes and Stroke
Junghyun Noh
The Journal of Korean Diabetes.2021; 22(1): 26. CrossRef
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
Metabolism.2021; 123: 154838. CrossRef

Drug/Regimen
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus: Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon; Diabetes Metab J. 2021;45(6):954-959. Published online November 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0173

55,104 View
368 Download
3 Web of Science
2 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.

Citations

Citations to this article as recorded by

2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
Diabetes & Metabolism Journal.2021; 45(4): 461. CrossRef

Drug/Regimen
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus: Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K.Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Seung Kim, Sei Hyun Baik; Diabetes Metab J. 2021;45(4):606-612. Published online September 9, 2020; DOI: https://doi.org/10.4093/dmj.2020.0047

5,047 View
139 Download
1 Crossref

Abstract PDF PubReader ePub

The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherapy with placebo were eligible to enrol. In the open-label, 28-week extension study, all enrolled patients received gemigliptin, regardless of the treatment received during the initial 24-week study period. The mean reduction±standard deviation (SD) in glycosylated hemoglobin (HbA1c) observed after 24 weeks of treatment (–0.6%±1.1%) was further decreased for the gemi-gemi group and the mean change in HbA1c at week 52 from baseline was –0.9%±1.2% (P<0.0001). For the pbo-gemi group, HbA1c decreased after they were switched to gemigliptin, and the mean change in HbA1c at week 52 from baseline was –0.7%±1.2% (P<0.0001). Furthermore, the overall incidence of adverse events demonstrated that gemigliptin was safe and well tolerated up to 52 weeks.

Citations

Citations to this article as recorded by

Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef

Complications
Diabetic Retinopathy and Related Clinical Practice for People with Diabetes in Korea: A 10-Year Trend Analysis: Yoo-Ri Chung, Kyoung Hwa Ha, Kihwang Lee, Dae Jung Kim; Diabetes Metab J. 2020;44(6):928-932. Published online July 10, 2020; DOI: https://doi.org/10.4093/dmj.2020.0096

5,197 View
178 Download
5 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

We performed a retrospective cohort study including people diagnosed with diabetes from 2006 to 2015 according to the Korean National Health Insurance Service-National Sample Cohort database, to analyze the changes in the prevalence, screening rate, and treatment patterns for diabetic retinopathy (DR) over 10 years. The proportion of people who underwent fundus screening for DR steadily increased over the past decade. The prevalence of DR increased from 13.4% in 2006 to 15.9% in 2015, while that of proliferative DR steadily decreased from 1.29% in 2006 to 1.16% in 2015. The proportion of patients undergoing retinal photocoagulation constantly decreased. The prevalence of DR increased over the past decade, while its severity seemed to have improved, with a decreased rate of proliferative DR and retinal photocoagulation. A higher proportion of patients underwent ophthalmic screening using fundus examination, but still less than 30% of patients with diabetes underwent comprehensive examination in 2015.

Citations

Citations to this article as recorded by

Variations in Electronic Health Record-Based Definitions of Diabetic Retinopathy Cohorts
Jimmy S. Chen, Ivan A. Copado, Cecilia Vallejos, Fritz Gerald P. Kalaw, Priyanka Soe, Cindy X. Cai, Brian C. Toy, Durga Borkar, Catherine Q. Sun, Jessica G. Shantha, Sally L. Baxter
Ophthalmology Science.2024; 4(4): 100468. CrossRef
Present and future screening programs for diabetic retinopathy: a narrative review
Andreas Abou Taha, Sebastian Dinesen, Anna Stage Vergmann, Jakob Grauslund
International Journal of Retina and Vitreous.2024;[Epub] CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data
Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko
BMC Public Health.2023;[Epub] CrossRef
Visual Acuity Outcomes in Diseases Associated with Reduced Visual Acuity: An Analysis of the National Health Insurance Service Database in Korea
Sang-Yeob Kim, Byeong-Yeon Moon, Hyun-Gug Cho, Dong-Sik Yu
International Journal of Environmental Research and Public Health.2022; 19(14): 8689. CrossRef
Prevalence of Diabetic Retinopathy in Undiagnosed Diabetic Patients: A Nationwide Population-Based Study
Han Na Jang, Min Kyong Moon, Bo Kyung Koo
Diabetes & Metabolism Journal.2022; 46(4): 620. CrossRef
Prevalence and Risk Factors of Diabetic Retinopathy in Diabetes People using Korean National Health and Nutrition Examination Survey VII
Ihn Sook Jeong, Chan Mi Kang
Journal of Korean Academy of Community Health Nursing.2022; 33(4): 408. CrossRef
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78)
Ja Young Jeon
Diabetes & Metabolism Journal.2021; 45(4): 613. CrossRef

Complications
Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports: Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi; Diabetes Metab J. 2020;44(2):349-353. Published online April 23, 2020; DOI: https://doi.org/10.4093/dmj.2020.0091

8,677 View
186 Download
65 Web of Science
71 Crossref

Abstract PDF PubReader

Since the first case was contracted by coronavirus disease-19 (COVID-19) in Daegu, Korea in February 2020, about 6,800 cases and 130 deaths have been reported on April 9, 2020. Recent studies have reported that patients with diabetes showed higher mortality and they had a worse prognosis than the group without diabetes. In poorly controlled patients with diabetes, acute hyperglycemic crises such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) also might be precipitated by COVID-19. Thus, intensive monitoring and aggressive supportive care should be needed to inadequately controlled patients with diabetes and COVID-19 infection. Here, we report two cases of severe COVID-19 patients with acute hyperglycemic crises in Korea.

Citations

Citations to this article as recorded by

Clinical Characteristics and Predictors of Mortality in Obese African-Americans with COVID-19: a Single-Center Retrospective Study
Pavani Reddy Garlapati, Suneet Kumar, Meet Patel, Bidyut Sarker, Benjamin Tiongson, Sreedhar Adapa, Sohail Abdul Salim, Mark K. Adler, Vijay Reddy Gayam
Journal of Racial and Ethnic Health Disparities.2023; 10(1): 160. CrossRef
Diabetes and the COVID-19 pandemic
Kamlesh Khunti, Jonathan Valabhji, Shivani Misra
Diabetologia.2023; 66(2): 255. CrossRef
Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
Journal of Korean Medical Science.2023;[Epub] CrossRef
COVID‐19 associated ketosis and diabetic ketoacidosis: A rapid review
Tharun T. Alamuri, Sandhya Mahesh, Kevin Dell'Aquila, Taylor Jan Leong, Rebecca Jennings, Tim Q. Duong
Diabetes, Obesity and Metabolism.2023; 25(7): 1785. CrossRef
Risks associated with acute pancreatitis (AP) with diabetic ketoacidosis (DKA) in COVID-19 patients: a literature review
Sundru Manjulata Devi, Annapurna Pamreddy, Venkata Ramana Narendra
Journal of Diabetes & Metabolic Disorders.2023; 22(1): 135. CrossRef
A Review of Hyperglycemia in COVID-19
Maryam Zahedi, Saba Kordrostami, Mohammadreza Kalantarhormozi, Marziyeh Bagheri
Cureus.2023;[Epub] CrossRef
A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19
Benjamin C. T. Field, Yue Ruan, Kinga A. Várnai, Jim Davies, Robert E. J. Ryder, Rajiv Gandhi, Sophie Harris, Dinesh Nagi, Dipesh Patel, Punith Kempegowda, Sarah H. Wild, Emma G. Wilmot, Kamlesh Khunti, Rustam Rea, Parth Narendran
Diabetes, Obesity and Metabolism.2023; 25(7): 2012. CrossRef
Diabetic Ketoacidosis in COVID-19 Patients: Clinical Characteristics and Outcomes – A Retrospective Study in a Single Tertiary Care Hospital, Dubai, United Arab Emirates
Hana AL Sughaiyer, Abeer AL Haj, Samia Murad Ibrahim Abdulrahman
Dubai Diabetes and Endocrinology Journal.2023; 29(2): 107. CrossRef
COVID-19 and diabetes
Artur Furga
Probacja.2023; 3: 235. CrossRef
COVID-19 SALGININDA DİYABET YÖNETİMİ VE HEMŞİRENİN ROLÜ
Dilek BÜYÜKKAYA BESEN, Merve DERVİŞOĞLU
Gazi Sağlık Bilimleri Dergisi.2022; 7(2): 78. CrossRef
Diabetic ketoacidosis and COVID-19: what have we learned so far?
Caio Oliveira de Sá-Ferreira, Camila Helena Macedo da Costa, João Campos Wiltgen Guimarães, Nathasha Souza Sampaio, Leticia de Moraes Lopes Silva, Larissa Paula de Mascarenhas, Nicollas Garcia Rodrigues, Talita Labonia dos Santos, Solange Campos, Esther C
American Journal of Physiology-Endocrinology and Metabolism.2022; 322(1): E44. CrossRef
COVID-19 and hyperglycaemic emergencies: perspectives from a developing country
Raisa Bhikoo, Marli Conradie-Smit, Gerhard Van Wyk, Sa’ad Lahri, Elizabeth Du Plessis, Jaco Cilliers, Susan Hugo, Ankia Coetzee
Journal of Endocrinology, Metabolism and Diabetes of South Africa.2022; 27(1): 42. CrossRef
Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients
Amr Shaaban Hanafy, Waseem M. Seleem, Hany A. Elkattawy
Clinical and Experimental Medicine.2022;[Epub] CrossRef
The COVID-19-diabetes mellitus molecular tetrahedron
Mehdi Mahmudpour, Katayoun Vahdat, Mohsen Keshavarz, Iraj Nabipour
Molecular Biology Reports.2022; 49(5): 4013. CrossRef
Diabetes and COVID-19; A Bidirectional Interplay
Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, Aikaterini Kountouri, Georgios Panagopoulos, Stavros Athanasopoulos, Eleni Korompoki, Ioannis Kalomenidis, Meletios A. Dimopoulos, Asimina Mitrakou
Frontiers in Endocrinology.2022;[Epub] CrossRef
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, Dong Xi, Tao Chen, Guang Chen, Hongwu Wang, Huiling Lu, Ming Wang, Lin Zhu, Junjian Hu, Tingting Liu, Ke Ma, Meifang Han, Xiaoping Luo
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Challenges in hyperglycemia management in critically ill patients with COVID-19
Rajesh Kethireddy, Darshan Gandhi, Asim Kichloo, Love Patel
World Journal of Critical Care Medicine.2022; 11(4): 219. CrossRef
New-Onset and Persistent Insulin-Dependent Diabetes in Patients With COVID-19: A Peruvian Experience
Anthony Ramos-Yataco, Emanuel A Salcedo Davila, Kelly Meza, Inga Harbuz-Miller
Cureus.2022;[Epub] CrossRef
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Cristina Rey-Reñones, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, María Grau
Biomedicines.2022; 10(9): 2089. CrossRef
SARS-CoV-2 Infections, Impaired Tissue, and Metabolic Health: Pathophysiology and Potential Therapeutics
Shailendra Pratap Singh, Aayushi Bhatnagar, Sujeet Kumar Singh, Sanjib K. Patra, Navjot Kanwar, Abhinav Kanwal, Salomon Amar, Ranata Manna
Mini-Reviews in Medicinal Chemistry.2022; 22(16): 2102. CrossRef
Collateral damage due to COVID-19
Farhan Fazal, Nitin Gupta, Wasim Khot, Yogiraj Ray
Tropical Doctor.2021; 51(1): 126. CrossRef
Diabetic emergencies during the COVID‐19 pandemic: A case–control study
M. S. B. Huda, S. Shaho, B. Trivedi, G. Fraterrigo, L. Chandrarajan, P. Zolfaghari, T. M. Dovey, C. G. Garrett, T. A Chowdhury
Diabetic Medicine.2021;[Epub] CrossRef
Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
Rebecca J. Vitale, Yannis K. Valtis, Marie E. McDonnell, Nadine E. Palermo, Naomi D.L. Fisher
AACE Clinical Case Reports.2021; 7(1): 10. CrossRef
Outcomes and Healthcare Provider Perceptions of Real-Time Continuous Glucose Monitoring (rtCGM) in Patients With Diabetes and COVID-19 Admitted to the ICU
Kenneth W. Chow, Danielle J. Kelly, Mary C. Rieff, Patricia A. Skala, Igor Kravets, Marina M. Charitou, Eric J. Morley, Rajarsi Gupta, Joshua D. Miller
Journal of Diabetes Science and Technology.2021; 15(3): 607. CrossRef
Diabetic ketoacidosis presented with COVID-19 infection: A rare case report
Deniz Çekiç, Selçuk Yaylacı, Sümeyye Çekiç, Kubilay İşsever, Hamad Dheir, Havva Kocayiğit, Mehmet Halil Öztürk, Oğuz Karabay
Journal of Clinical Medicine of Kazakhstan.2021; 18(1): 79. CrossRef
Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
Hee-Sung Kim, Minseok Kang, Gilwon Kang
BMC Infectious Diseases.2021;[Epub] CrossRef
Increased Incidence of Pediatric Diabetic Ketoacidosis After COVID-19: A Two-Center Retrospective Study in Korea
Min Jeong Han, Jun Ho Heo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 783. CrossRef
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
Andrey Santos, Daniéla Oliveira Magro, Rosana Evangelista-Poderoso, Mario José Abdalla Saad
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins’ Mimicry of Human Protein Interactions
Hale Yapici-Eser, Yunus Emre Koroglu, Ozgur Oztop-Cakmak, Ozlem Keskin, Attila Gursoy, Yasemin Gursoy-Ozdemir
Frontiers in Human Neuroscience.2021;[Epub] CrossRef
COVID-19 and Diabetic Ketoacidosis: Report of Eight Cases
Balraj Singh, Prem Patel , Parminder Kaur , Nicole Majachani, Michael Maroules
Cureus.2021;[Epub] CrossRef
Machine Learning Applied to Clinical Laboratory Data in Spain for COVID-19 Outcome Prediction: Model Development and Validation
Juan L Domínguez-Olmedo, Álvaro Gragera-Martínez, Jacinto Mata, Victoria Pachón Álvarez
Journal of Medical Internet Research.2021; 23(4): e26211. CrossRef
Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
Ines Bilic Curcic, Maja Cigrovski Berkovic, Tomislav Kizivat, Silvija Canecki Varzic, Robert Smolic, Martina Smolic
World Journal of Diabetes.2021; 12(6): 780. CrossRef
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Cyril P. Landstra, Eelco J. P. de Koning
Frontiers in Endocrinology.2021;[Epub] CrossRef
Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
James R. Gavin, Clifford J. Bailey
Diabetes Technology & Therapeutics.2021; 23(S3): S-19. CrossRef
Evaluation of Characteristics and Outcomes for Patients with Diabetic Ketoacidosis (DKA) With and Without COVID-19 in Elmhurst Queens During Similar Three-Month Periods in 2019 and 2020
Urja Patel, Linda Deluxe, Carlos Salama, Aaron Ross Jimenez, Adrian Whiting, Cedrick Lubin, Nancy Tarlin
Cureus.2021;[Epub] CrossRef
Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study
Shivani Misra, Emma Barron, Eszter Vamos, Stephen Thomas, Ketan Dhatariya, Partha Kar, Bob Young, Kamlesh Khunti, Jonathan Valabhji
The Lancet Diabetes & Endocrinology.2021; 9(10): 671. CrossRef
Diabetes mellitus and COVID-19: Understanding the association in light of current evidence
Saikat Sen, Raja Chakraborty, Pratap Kalita, Manash Pratim Pathak
World Journal of Clinical Cases.2021; 9(28): 8327. CrossRef
Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China
Shuiping Dai, Bennan Zhao, Dafeng Liu, Yongzhao Zhou, Yaling Liu, Lijuan Lan, Yalun Li, Wenxin Luo, Yilan Zeng, Weimin Li
International Journal of General Medicine.2021; Volume 14: 7207. CrossRef
Diabetic ketoacidosis in patients with SARS-CoV-2: a systematic review and meta-analysis
Saad Alhumaid, Abbas Al Mutair, Zainab Al Alawi, Ali A. Rabaan, Mohammed A. Alomari, Sadiq A. Al Salman, Ahmed S. Al-Alawi, Mohammed H. Al Hassan, Hesham Alhamad, Mustafa A. Al-kamees, Fawzi M. Almousa, Hani N. Mufti, Ali M. Alwesabai, Kuldeep Dhama, Jaff
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
In-hospital clinical complications of COVID-19: a brief overview
Kevin John John, Jemimah Nayar, Ajay Kumar Mishra, Vijairam Selvaraj, Mohammad Saud Khan, Amos Lal
Future Virology.2021; 16(11): 717. CrossRef
Combined Hyperglycemic Hyperosmolar Syndrome and Diabetic Ketoacidosis Associated with COVID-19 in a Pediatric Patient
Yu Shan Tseng, Bradley Tilford, Usha Sethuraman, Katherine Cashen, Mehmet Doganay
Case Reports in Critical Care.2021; 2021: 1. CrossRef
Toddler With New Onset Diabetes and Atypical Hemolytic-Uremic Syndrome in the Setting of COVID-19
Faraz Alizadeh, Amanda O’Halloran, Areej Alghamdi, Charlotte Chen, Maria Trissal, Avram Traum, Danielle DeCourcey
Pediatrics.2021;[Epub] CrossRef
A Complicated Case of COVID-19 and Hyperglycemic Hyperosmolar Syndrome in an Adolescent Male
Anisha Gohil, Stefan Malin, Kamal Abulebda, Tamara S. Hannon
Hormone Research in Paediatrics.2021; 94(1-2): 71. CrossRef
COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
Asirvatham Alwin Robert, Mohamed Abdulaziz Al Dawish
Current Diabetes Reviews.2021;[Epub] CrossRef
A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
Hong Nyun Kim, Jang Hoon Lee, Hun Sik Park, Dong Heon Yang, Se Yong Jang, Myung Hwan Bae, Yongkeun Cho, Shung Chull Chae, Yong-Hoon Lee
Journal of Korean Medical Science.2020;[Epub] CrossRef
Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature
Rimesh Pal, Mainak Banerjee, Urmila Yadav, Sukrita Bhattacharjee
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 1563. CrossRef
Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations
Nadine E Palermo, Archana R Sadhu, Marie E McDonnell
The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): 2819. CrossRef
A Case of Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in a Patient With COVID-19
Shemitha Rafique, Fahad W Ahmed
Cureus.2020;[Epub] CrossRef
COVID’s Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19

Maureen Czick, Christine Shapter, Robert Shapter
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3169. CrossRef
Letter: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
Ja Young Jeon
Diabetes & Metabolism Journal.2020; 44(3): 480. CrossRef
COVID-19 in people with diabetes: understanding the reasons for worse outcomes
Matteo Apicella, Maria Cristina Campopiano, Michele Mantuano, Laura Mazoni, Alberto Coppelli, Stefano Del Prato
The Lancet Diabetes & Endocrinology.2020; 8(9): 782. CrossRef
Diabetes and COVID-19: Global and regional perspectives
In-Kyung Jeong, Kun Ho Yoon, Moon Kyu Lee
Diabetes Research and Clinical Practice.2020; 166: 108303. CrossRef
Hyperglycemia, Hypertriglyceridemia, and Acute Pancreatitis in COVID-19 Infection
Chiranjeevi Gadiparthi, Mehak Bassi, Balaji Yegneswaran, Sammy Ho, Capecomorin S. Pitchumoni
Pancreas.2020; 49(7): e62. CrossRef
Response: Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports (Diabetes Metab J 2020;44:349–53)
Na-young Kim, Eunyeong Ha, Jun Sung Moon, Yong-Hoon Lee, Eun Young Choi
Diabetes & Metabolism Journal.2020; 44(3): 484. CrossRef
Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature
Pavan Kumar Reddy, Mohammad Shafi Kuchay, Yatin Mehta, Sunil Kumar Mishra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1459. CrossRef
COVID-19 and diabetes: What have we learned so far?
Nida Taher, Mohammed SB Huda, Tahseen A Chowdhury
Clinical Medicine.2020; 20(4): e87. CrossRef
High dose ascorbic acid treatment in COVID-19 patients raised some problems in clinical chemistry testing
Fatih Yesildal, Ferruh Kemal Isman
Turkish Journal of Biochemistry.2020; 45(5): 491. CrossRef
Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
Junghyun Noh, Hyun-Ha Chang, In-Kyung Jeong, Kun Ho Yoon
Diabetes & Metabolism Journal.2020; 44(3): 372. CrossRef
Practical considerations for pregnant women with diabetes and severe acute respiratory syndrome coronavirus 2 infection
Glenn P. Boyles, Stephen Thung, Steven G. Gabbe, Mark B. Landon, Maged M. Costantine
American Journal of Obstetrics & Gynecology MFM.2020; 2(4): 100210. CrossRef
Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series
Eleni Armeni, Umaira Aziz, Sulmaaz Qamar, Sadia Nasir, Chidambaram Nethaji, Rupert Negus, Nicholas Murch, Huw Clarke Beynon, Pierre Bouloux, Miranda Rosenthal, Sidrah Khan, Ahmed Yousseif, Ravi Menon, Efthimia Karra
The Lancet Diabetes & Endocrinology.2020; 8(8): 660. CrossRef
Development of a tablet PC-based portable device for colorimetric determination of assays including COVID-19 and other pathogenic microorganisms
Woo Sik Yoo, Hyung Soo Han, Jung Gon Kim, Kitaek Kang, Hyo-Sung Jeon, Jin-Young Moon, Hyeonmi Park
RSC Advances.2020; 10(54): 32946. CrossRef
Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation
Akhil Vaid, Sulaiman Somani, Adam J Russak, Jessica K De Freitas, Fayzan F Chaudhry, Ishan Paranjpe, Kipp W Johnson, Samuel J Lee, Riccardo Miotto, Felix Richter, Shan Zhao, Noam D Beckmann, Nidhi Naik, Arash Kia, Prem Timsina, Anuradha Lala, Manish Paran
Journal of Medical Internet Research.2020; 22(11): e24018. CrossRef
COVID-19: the endocrine opportunity in a pandemic
Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Souvik Dubey, Rishi T. Guria, Chandra B. Sharma, Sanjay Kalra
Minerva Endocrinologica.2020;[Epub] CrossRef
Management of Diabetes in Coronavirus Disease 2019: Prognosis and Practical Issues
Hye Soon Kim
The Journal of Korean Diabetes.2020; 21(3): 120. CrossRef
Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19
Mohammad Shafi Kuchay, Pavan Kumar Reddy, Sakshi Gagneja, Anu Mathew, Sunil Kumar Mishra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2039. CrossRef
Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series
Ibrahim Alsadhan, Shahad Alruwashid, Maram Alhamad, Sarah Alajmi, Sara Alshehri, Eman Alfadhli, Aishah Ekhzaimy
Current Therapeutic Research.2020; 93: 100609. CrossRef
Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients
F.-J. Prado-Galbarro, C. Sanchez-Piedra, A.E. Gamiño-Arroyo, C. Cruz-Cruz
Public Health.2020; 189: 66. CrossRef
SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells
Katie C. Coate, Jeeyeon Cha, Shristi Shrestha, Wenliang Wang, Luciana Mateus Gonçalves, Joana Almaça, Meghan E. Kapp, Maria Fasolino, Ashleigh Morgan, Chunhua Dai, Diane C. Saunders, Rita Bottino, Radhika Aramandla, Regina Jenkins, Roland Stein, Klaus H.
Cell Metabolism.2020; 32(6): 1028. CrossRef
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
Amisha Wallia, Grace Prince, Emilie Touma, Malek El Muayed, Jane Jeffrie Seley
Current Diabetes Reports.2020;[Epub] CrossRef
Recovery From Acute Kidney Injury With Diabetic Ketoacidosis Following SARS-CoV-2 Infection: A Case Report and Literature Review
Chang Xu, Umer Zia
Cureus.2020;[Epub] CrossRef
The Outbreak of COVID-19 and Diabetes in Korea: “We Will Find a Way as We Have Always Done”
Kyu Chang Won, Kun Ho Yoon
Diabetes & Metabolism Journal.2020; 44(2): 211. CrossRef

Cardiovascular risk/Epidemiology
Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction: Jae-Wook Chung, Yeong-Seon Park, Jeong-Eon Seo, Yeseul Son, Cheol-Woo Oh, Chan-Hee Lee, Jong-Ho Nam, Jung-Hee Lee, Jang-Won Son, Ung Kim, Jong-Seon Park, Kyu-Chang Won, Dong-Gu Shin; Diabetes Metab J. 2021;45(2):270-274. Published online April 16, 2020; DOI: https://doi.org/10.4093/dmj.2019.0164

5,688 View
119 Download
8 Web of Science
8 Crossref

Graphical Abstract Abstract PDF PubReader ePub

This study aimed to determine the impact of dysglycemia on myocardial injury and cardiac dysfunction in acute myocardial infarctions (AMIs). From 2005 to 2016, a total of 1,593 patients with AMIs who underwent percutaneous coronary intervention were enrolled. The patients were classified into five groups according to the admission glucose level: ≤80, 81 to 140, 141 to 200, 201 to 260, and ≥261 mg/dL. The clinical and echocardiographic parameters and 30-day mortality were analyzed. The peak troponin I and white blood cell levels had a positive linear relationship to the admission glucose level. The left ventricular ejection fraction had an inverted U-shape trend, and the E/E' ratio was U-shaped based on euglycemia. The 30-day mortality also increased as the admission glucose increased, and the cut-off value for predicting the mortality was 202.5 mg/dL. Dysglycemia, especially hyperglycemia, appears to be associated with myocardial injury and could be another adjunctive parameter for predicting mortality in patients with AMIs.

Citations

Citations to this article as recorded by

Optimal Low-Density Lipoprotein Cholesterol Levels in Adults Without Diabetes Mellitus: A Nationwide Population-Based Study Including More Than 4 Million Individuals From South Korea
Ji Hye Huh, Sang Wook Park, Tae-Hwa Go, Dae Ryong Kang, Sang-Hak Lee, Jang-Young Kim
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Association of admission hyperglycemia and all-cause mortality in acute myocardial infarction with percutaneous coronary intervention: A dose–response meta-analysis
Shao-Yong Cheng, Hao Wang, Shi-Hua Lin, Jin-Hui Wen, Ling-Ling Ma, Xiao-Ce Dai
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Basic types of the first-day glycemia in acute myocardial infarction: Prognostic, diagnostic, threshold and target glycemia
Goran Koracevic, Milan Djordjevic
Primary Care Diabetes.2021; 15(3): 614. CrossRef
Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction (Diabetes Metab J 2021;45:270-4)
Bo-Yeon Kim
Diabetes & Metabolism Journal.2021; 45(5): 787. CrossRef
Clinical Impact of Dysglycemia in Patients with an Acute Myocardial Infarction (Diabetes Metab J 2021;45:270-4)
Chan-Hee Lee
Diabetes & Metabolism Journal.2021; 45(5): 791. CrossRef
The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2021; 36(5): 977. CrossRef
Effect of Admission Hyperglycemia on Short-Term Prognosis of Patients with Non-ST Elevation Acute Coronary Syndrome without Diabetes Mellitus
Wei Liu, Zhijuan Li, Shiying Xing, Yanwei Xu, Gaetano Santulli
Journal of Diabetes Research.2021; 2021: 1. CrossRef

Complications
Short-Term Walking Outcomes in Diabetic and Non-Diabetic Unilateral Transtibial Amputees: Dong Gyu Kwak, Jeong-Yong Hur, Jun Sung Moon, Min Cheol Chang; Diabetes Metab J. 2020;44(4):614-618. Published online November 4, 2019; DOI: https://doi.org/10.4093/dmj.2019.0080

4,181 View
85 Download

Abstract PDF PubReader ePub: This study compared short-term walking outcomes in diabetic amputees after prosthesis fitting compared to that in non-diabetic amputees. We retrospectively investigated walking outcomes at 3 months after starting gait training with a prosthesis. Forty-four unilateral transtibial amputees with (n=18) and without diabetes (n=26) were included. At 3 months after gait training with a prosthesis, only 2/18 (11.1%) and 3/18 (16.7%) diabetic amputees were capable of independent outdoor and indoor walking without cane, respectively. However, 21/26 (80.8%) and 24/26 (92.3%) non-diabetic amputees were capable of independent outdoor and indoor walking without cane, respectively. With assistance of cane, most of non-diabetic amputees (n=24, 92.3%) were capable of walking in both outdoor and indoor but only seven (38.9%) and nine (50.0%) diabetic amputees were capable, respectively. Thus, short-term walking outcome were poor in transtibial amputee with diabetes compare to those without diabetes, and these results suggest intensive rehabilitation would be needed to them.

Drug/Regimen
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice: Mi-Jin Kim, Na-young Kim, Yun-A Jung, Seunghyeong Lee, Gwon-Soo Jung, Jung-Guk Kim, In-Kyu Lee, Sungwoo Lee, Yeon-Kyung Choi, Keun-Gyu Park; Diabetes Metab J. 2020;44(1):186-192. Published online October 31, 2019; DOI: https://doi.org/10.4093/dmj.2018.0271

5,682 View
97 Download
10 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader

Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated protective effects against diabetic kidney disease. However, the anti-fibrotic effect of evogliptin, a DPP-4 inhibitor, has not been studied. Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. Immunohistochemistry and Western blotting demonstrated that evogliptin treatment inhibits pro-fibrotic gene expressions and extracellular matrix production. In vitro findings showed that the beneficial effects of evogliptin on renal fibrosis are mediated by inhibition of the transforming growth factor-β/Smad3 signaling pathway. The present study demonstrates that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.

Citations

Citations to this article as recorded by

Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis
Birte Ohm, Isabelle Moneke, Wolfgang Jungraithmayr
British Journal of Pharmacology.2023; 180(22): 2846. CrossRef
Linagliptin ameliorates pulmonary fibrosis in systemic sclerosis mouse model via inhibition of endothelial-to-mesenchymal transition
Biwei Pei, Na Zhang, Tingting Pang, Gengyun Sun
Molecular and Cellular Biochemistry.2022; 477(4): 995. CrossRef
Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef
Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells
Hye-Young Seo, So-Hee Lee, Eugene Han, Jae Seok Hwang, Sol Han, Mi Kyung Kim, Byoung Kuk Jang
International Journal of Molecular Sciences.2022; 23(19): 11636. CrossRef
Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma
Hyunyee Yoon, Su Hee Cho, Yu Rim Seo, Kyung-Sang Yu, Sung Sup Park, Moon Jung Song
Analytical Biochemistry.2021; 612: 113952. CrossRef
Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside
Sungjin Chung, Gheun-Ho Kim
Life.2021; 11(5): 389. CrossRef
Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?
Xin Huang, Yimin Khoong, Chengyao Han, Dai Su, Hao Ma, Shuchen Gu, Qingfeng Li, Tao Zan
Frontiers in Physiology.2021;[Epub] CrossRef
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef
Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha, Eun Seok Kang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4113. CrossRef
Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: A meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Aishwarya Krishnamurthy, LokeshKumar Sharma, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2020; 24(5): 434. CrossRef

First
Prev
Page of 3
Next
Last

Brief report